Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum-Reference-Cited by-同舟云学术

Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum

Published:2022-05 Issue: Volume:1199 Page:123245
ISSN:1570-0232
Container-title:Journal of Chromatography B
language:en
Short-container-title:Journal of Chromatography B

Author:

Ishikawa Emi^ORCID,Yokoyama Yuta,Chishima Haruna,Kuniyoshi Ouki,Sato Itaru^ORCID,Nakaya Naoki,Nakajima Hideo^ORCID,Kimura Motonori,Hakamata Jun,Suehiro Naoya,Nakada Hideo,Ikemura Shinnosuke,Jibiki Aya,Kawazoe Hitoshi^ORCID,Muramatsu Hiroshi,Suzuki Sayo,Nakamura Tomonori

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry

Reference38 articles.

1. FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: Safety, tolerability, plasma concentration monitoring, and management;Solassol;Biomolecules.,2019

2. Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: A meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non–small cell lung cancer;Ding;J. Thorac. Oncol.,2017

3. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial;Wu;Lancet Oncol.,2017

4. FLAURA Investigators, Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer;Soria;N. Engl. J. Med.,2018

5. Afatinib Therapy: Practical management of adverse events with an oral agent for non-small cell lung cancer treatment;Edwards;Clin. J. Oncol. Nurs.,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous determination of icotinib, osimertinib, aumolertinib, and anlotinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS;Journal of Pharmaceutical and Biomedical Analysis;2024-12

2. AFATINIB-A COMPREHENSIVE REVIEW OF ANALYTICAL METHODS DEVELOPED IN PHARMACEUTICALS AND BIOLOGICAL MATRICES;International Journal of Applied Pharmaceutics;2024-07-07

3. Current Bioanalysis of Molecularly Targeted Drugs Using Liquid Chromatography–Tandem Mass Spectrometry;CHROMATOGRAPHY;2023-06-20

4. Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients;Analytical Biochemistry;2023-05

5. Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study;Investigational New Drugs;2023-01-13